Back to Stakeholders

Psychedelic Alpha (Pα) is an independent, data-driven psychedelic media, research and advisory platform, founded in 2020 by Josh Hardman and based in London. It publishes the widely read weekly Psychedelic Bulletin newsletter alongside closely followed trackers of psychedelic drug development and of psychedelic law and policy, and provides advisory and consultancy services to investors, philanthropists, government agencies, startups and established firms. It is known for cutting through hype to surface what matters in the development, regulation and commercialisation of psychedelic medicines.

Consultancy & Advisory Snapshot

Commercial Strategy Consulting

Geography

Global

Coverage

Global

Psychedelic Focus

Explicit Psychedelic Focus

Engagement

Active

Pipeline Stage Coverage

Clinical DevelopmentRegulatory AffairsCommercialization & Launch

Client Types

Drug DevelopersInvestors / FundsGovernment / Public SectorNon-Profits / Advocacy Organizations

Consultancy Notes

Independent data-driven news and intelligence platform founded in 2020 by Josh Hardman, registered as Psy Alpha Ltd in England and Wales, covering psychedelic drug development, regulation and commercialisation. Alongside its bulletins, drug development tracker and legalisation tracker, it runs a selective advisory practice serving investors, philanthropists, government agencies, startups and large firms. Engagements range from one-off research calls and strategy sessions to retainer-based advisory and corporate briefings.

Verification

Verified

Last Verified

Jul 11, 2026

Primary Service Link

Media & Communication Snapshot

Psychedelic News & Analysis

Cadence

Weekly

Access

Freemium

Psychedelic Focus

Explicit Psychedelic Focus

Verification

Verified

Audience

InvestorsIndustry ProfessionalsResearchersPolicymakers

Coverage Focus

Business & IndustryPolicy & LegalResearch & Science

Media Notes

Psychedelic Alpha is an independent, data-driven news and intelligence platform covering psychedelic drug development, regulation, commercialisation and policy reform. It maintains widely cited resources including a drug development pipeline tracker, a legalisation and decriminalisation policy map and a sector job board. A free tier offers weekly news roundups, while the paid Pa+ subscription adds bulletins, interviews and deep-dive analysis.

Verification

Verified

Last Verified

Jul 11, 2026

Primary Media Link

Quick Facts

Type
Other
HQ
United Kingdom
Website
Visit